POZEN Product Pipeline Status

Migraine Market
Unlike some other multi-billion dollar prescription markets, the migraine market is significantly underserved. There are an estimated 25 to 30 million migraine sufferers in the U.S. alone. Only half of U.S. migraine sufferers are currently diagnosed by physicians and only two-thirds of these diagnosed patients use prescription medications. We believe one explanation for the underserved market may be that some current therapeutic alternatives lack efficacy or produce undesirable side effects. Over-the-counter medicines are generally the first step for many migraine patients, however, they are unable to provide the sustained pain relief associated with prescription medicines.

Today, most of the multi-billion dollar worldwide prescription market is represented by triptans. Although this class of drug represents a major breakthrough in migraine care, fewer than 40% of triptan patients consistently get 24-hour pain relief. Also, triptan use is not recommended in patients with known cardiovascular risk factors. More on Migraines

Other Therapeutic Areas
Beyond the field of migraine, we are looking to develop products in new areas where there is an unmet need and where we can improve a patient's quality of life. Our drug development experts have participated in the development and approval of over 40 drugs, spanning areas such as migraine, gastrointestinal, respiratory, oncology and infectious diseases.